Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure

被引：20
|
作者：
Nathwani, Nitya [1 ]
Krishnan, Amrita Y. [1 ]
Huang, Qin [2 ]
Kim, Young [2 ]
Karanes, Chatchada [1 ]
Smith, Eileen P. [1 ]
Forman, Stephen J. [1 ]
Sievers, Eric [3 ]
Thomas, Sandra H. [1 ]
Chen, Robert W. [1 ]
机构：
[1] City Hope Natl Med Ctr, Dept Hematol HCT, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA
[3] Seattle Genet, Bothell, WA USA
来源：
LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 10期
关键词：
STEM-CELL TRANSPLANTATION; DISEASE; TUBULIN; TRIAL;
D O I：
10.3109/10428194.2012.666543
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2051 / 2053
页数：3
相关论文
共 50 条
  • [21] DURABLE COMPLETE REMISSIONS IN A PIVOTAL PHASE 2 STUDY OF SGN-35 (BRENTUXIMAB VEDOTIN) IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL)
    Younes, A.
    Gopal, A. K.
    Smith, S. E.
    Ansell, S. M.
    Rosenblatt, J. D.
    Savage, K. J.
    Connors, J. M.
    Engert, A.
    Larsen, E. K.
    Kennedy, D. A.
    Sievers, E. L.
    Chen, R.
    ANNALS OF ONCOLOGY, 2011, 22 : 138 - 138
  • [22] Brentuximab vedotin (SGN-35) in Hodgkin's lymphoma patients with relapsed after autologous peripheral blood stem-cell transplantation
    Erdem, G.
    Karadurmus, N.
    Ozaydin, S.
    Karacalioglu, A. O.
    Yeginer, C.
    Ozturk, M.
    Ataergin, S.
    Nevruz, O.
    Cetin, T.
    Arpaci, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S853 - S853
  • [23] Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
    Shustov, Andrei R.
    Advani, Ranjana
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey
    Ramachandren, Radhakrishnan
    Fanale, Michelle A.
    Connors, Joseph M.
    Yang, Yin
    Sievers, Eric L.
    Kennedy, Dana A.
    Pro, Barbara
    BLOOD, 2010, 116 (21) : 423 - 424
  • [24] Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels
    Bashey, S.
    Krathen, M.
    Sutherland, K.
    Sundram, U.
    Lingala, B.
    Horwitz, S.
    Hoppe, R.
    Pulitzer, M.
    Advani, R.
    Kim, Y.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 : S95 - S95
  • [25] CD30 Expression Does Not Predict Response To Brentuximab Vedotin
    Xu, Mina
    Katz, Samuel
    MODERN PATHOLOGY, 2015, 28 : 389A - 389A
  • [26] Expression of CD30 as a biomarker to predict response to brentuximab vedotin
    Xu, Mina L.
    Acevedo-Gadea, Carlos
    Seropian, Stuart
    Katz, Samuel G.
    HISTOPATHOLOGY, 2016, 69 (01) : 155 - 158
  • [27] CD30 Expression Does Not Predict Response To Brentuximab Vedotin
    Xu, Mina
    Katz, Samuel
    LABORATORY INVESTIGATION, 2015, 95 : 389A - 389A
  • [28] Phase II trial of Brentuximab vedotin (SGN-35) for CD30+cutaneous T-cell lymphomas and lymphoproliferative disorders
    Duvic, M.
    Tetzlaff, H.
    Gangar, P.
    Clos, A. L.
    Talpur, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S180 - S180
  • [29] SAFETY AND EFFICACY OF BRENTUXIMAB VEDOTIN (SGN-35) IN HODGKIN LYMPHOMA PATIENTS UNDERGOING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT FOLLOWING A RELAPSE AFTER AUTOLOGOUS TRANSPLANT
    Zallio, F.
    Busca, A.
    Mordini, N.
    Ferrando, F.
    Bruno, B.
    Salvi, F.
    Levis, A.
    Pini, M.
    HAEMATOLOGICA, 2014, 99 : 431 - 432
  • [30] Safety and Efficacy of Brentuximab Vedotin (SGN-35) in Hodgkin Lymphoma Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplant Following a Relapse After Autologous Transplant
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (08) : 20 - 20
12345